Pure Bioscience: (OTC: PURE)
$0.28
0.00 (0.00%)
Volume 391,855
May 17 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 0.26 - 0.40 |
| 52wk Low - High | 0.26 - 0.40 |
| Previous Close | 0.00 |
| Avg. Volume | 103,944 |
| Industry | MED PRODUCTS |
| Market Cap | 4.83 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.63 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.71 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
177 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.71 |
| Current Quarter Estimate | -0.16 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 06-05-2013 |
| EPS Last Year | -2.19 |
| Expected Earnings Growth | NA |
Company Description
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of green products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| PURE BIOSCIENCE | PURE | 0.44 | |
|
| CONCEPTUS INC | CPTS | 30.98 | |
|
| ATRICURE INC | ATRC | 8.99 | |
|
| INVIVO THERAPT | NVIV | 2.90 | |
|
| TRANS1 INC | TSON | 1.59 | |
|
| ABAXIS INC | ABAX | 44.22 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 73.04 | |
|
| BIO-RAD LABS -A | BIO | 116.12 | |
|
| BIOLIFE SOL INC | BLFS | 0.38 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -2.19 |
| Sales | 1 |
| Net Income | -8 |
| Price/Earnings | NA |
| Price/Book | 2.78 |
| Price/Cash Flow | NA |
| Price/Sales | 6.84 |
News
PURE Bioscience Receives Favorable NASDAQ Listing Decision - Benzinga
Apr 25, 2013
Pure Shares Surge on Disinfectant Demand - InvestorPlace
Jan 14, 2013
PURE Bioscience Reports Operating Results (10-K) - GuruFocus
Oct 29, 2012
Global Markets Take It on the Chin - Minyanville
Oct 23, 2012
4 Stocks Under $5 Ripping Higher - TheStreet.com
Oct 9, 2012
PURE Biosences Says Continuing to Test SDC in Produce - Benzinga
Oct 3, 2012
PURE Bioscience Partners with Italian Export Company TICE - Benzinga
Sep 27, 2012
PURE Bioscience Regains Compliance with Nasdaq Listing Requirements - Benzinga
Sep 24, 2012
Broker Recommendations
| Current ABR | 3.00 |
| ABR (Last Week) | 3.00 |
| # of recs in ABR | 1 |
| Average Target Price | 1.50 |
| Industry Rank by ABR | 177 out of 265 |
| Rank in Industry | 5 out of 73 |
